Cost-effectiveness of strict "get to goal" treatment directives in the treatment of younger patients with newly diagnosed type 2 diabetes mellitus (T2DM)

被引：0

作者：

Willis, M. ^{[1
]}

Borg, S. ^{[1
]}

Persson, U. ^{[1
]}

Neslusan, C. ^{[2
]}

机构：

[1] Swedish Inst Hlth Econ, IHE, Lund, Sweden

[2] Johnson & Johnson, Raritan, NJ USA

来源：

VALUE IN HEALTH | 2007年 / 10卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)64969-8

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A260 / A260

页数：1

共 50 条

[31] COST-EFFECTIVENESS OF ONCE WEEKLY DULAGLUTIDE 1.5 MG VERSUS ONCE DAILY LIRAGLUTIDE 1.8 MG FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CHINA
Han, S.
Guo, W. J.
Wang, K.
McKaig, S.
Strizek, A. A.
Shi, L. W.
VALUE IN HEALTH, 2019, 22 : S167 - S167
[32] Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naive Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
Shafie, Asrul Akmal
Ng, Chin Hui
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 333 - 343
[33] Cost-effectiveness of treatment of type 2 diabetes
Eastman, RC
DIABETES CARE, 1998, 21 (03) : 464 - 465
[34] RESEARCH ON THE INCIDENCE AND COST OF HYPOGLYCEMIA EPISODE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Zheng, Y.
Wu, J.
Oesterle, A.
VALUE IN HEALTH, 2012, 15 (07) : A504 - A505
[35] ASSESSMENT OF THE KEY DRIVERS OF COST-EFFECTIVENESS IN THE ECONOMIC MODELLING OF CANAGLIFLOZIN (CANA) VERSUS GLIMEPIRIDE (GLIM) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK SETTING
Thompson, G.
Willis, M.
Johansen, P.
Neslusan, C.
Schroeder, M.
Girod, I
VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
[36] Consideration of Comorbidities in Treatment Choice for Patients with Type 2 Diabetes (T2DM)
Ritchey, Mary E.
Engel, Samuel S.
Liu, Zhiwen
Ntabadde, Catherine
Senderak, Michael
Shankar, Ravi
Qiu, Ying
Radican, Larry
Rajpathak, Swapnil
Brodovicz, Kimberly G.
DIABETES, 2014, 63 : A636 - A636
[37] Achievement of Diabetes-related Treatment Goals with Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Blonde, Lawrence
Woo, Vincent
Mathieu, Chantal
Yee, Jacqueline
Vijapurkar, Ujjwala
Meininger, Gary
DIABETES, 2014, 63 : A284 - A284
[38] Newly diagnosed patients with type 2 diabetes mellitus are satisfied with insulin treatment
Lingvay, I.
Kaloyanova, P. F.
Raskin, P.
DIABETOLOGIA, 2006, 49 : 527 - 527
[39] Symptoms and Correlations in Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) with Nonalcoholic Fatty Liver Disease (NAFLD)
Mukherjee, Supriyo
DIABETES, 2024, 73
[40] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in the Canadian payer setting
Kapor, Jovana
Minshall, Michael E.
Tunis, Sandra L.
Conner, Chris
Mccormick, John
Seager, Christine
Groleau, Danielle
DIABETES, 2008, 57 : A98 - A98

← 1 2 3 4 5 →